- Home
- ECOR vs SWZ Comparison
ECOR vs SWZ Comparison
Compare ECOR & SWZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ECOR
- SWZ
- Stock Information
- Founded
- ECOR 2005
- SWZ 1986
- Country
- ECOR United States
- SWZ United States
- Employees
- ECOR N/A
- SWZ N/A
- Industry
- ECOR Biotechnology: Electromedical & Electrotherapeutic Apparatus
- SWZ Finance Companies
- Sector
- ECOR Health Care
- SWZ Finance
- Exchange
- ECOR Nasdaq
- SWZ Nasdaq
- Market Cap
- ECOR 111.3M
- SWZ 98.3M
- IPO Year
- ECOR 2018
- SWZ N/A
- Fundamental
- Price
- ECOR $15.90
- SWZ $8.45
- Analyst Decision
- ECOR Strong Buy
- SWZ
- Analyst Count
- ECOR 1
- SWZ 0
- Target Price
- ECOR $25.00
- SWZ N/A
- AVG Volume (30 Days)
- ECOR 144.8K
- SWZ 14.2K
- Earning Date
- ECOR 03-12-2025
- SWZ 01-01-0001
- Dividend Yield
- ECOR N/A
- SWZ 6.59%
- EPS Growth
- ECOR N/A
- SWZ N/A
- EPS
- ECOR N/A
- SWZ N/A
- Revenue
- ECOR $23,327,000.00
- SWZ N/A
- Revenue This Year
- ECOR $59.81
- SWZ N/A
- Revenue Next Year
- ECOR $38.49
- SWZ N/A
- P/E Ratio
- ECOR N/A
- SWZ N/A
- Revenue Growth
- ECOR 74.10
- SWZ N/A
- 52 Week Low
- ECOR $5.32
- SWZ $7.12
- 52 Week High
- ECOR $18.67
- SWZ $8.57
- Technical
- Relative Strength Index (RSI)
- ECOR 53.73
- SWZ 75.18
- Support Level
- ECOR $15.50
- SWZ $7.58
- Resistance Level
- ECOR $16.12
- SWZ $8.47
- Average True Range (ATR)
- ECOR 1.20
- SWZ 0.09
- MACD
- ECOR -0.31
- SWZ 0.11
- Stochastic Oscillator
- ECOR 40.17
- SWZ 97.96
About ECOR electroCore Inc.
electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients and the prevention of migraine in adult patients, The use of gammaCore by adolescent patients and Treatment of hemicrania continua and paroxysmal hemicrania in adult patients.
About SWZ Swiss Helvetia Fund Inc. (The)
Swiss Helvetia Fund Inc is a non-diversified, closed-end investment company. Its investment objective is to seek long-term capital appreciation through investment in equity and equity-linked securities of Swiss companies. The group invests in various sectors such as pharmaceuticals, food and beverage, industrial goods and services, banks, personal and household goods, construction and materials, biotechnology, medical equipment, chemicals, technology, financial services, insurance, and retail.